Is Lifecore Biomedical Stock a Good Investment?
Lifecore Biomedical Investment Advice | LFCR |
- Examine Lifecore Biomedical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Lifecore Biomedical's leadership team and their track record. Good management can help Lifecore Biomedical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Lifecore Biomedical's business and its evolving consumer preferences.
- Compare Lifecore Biomedical's performance and market position to its competitors. Analyze how Lifecore Biomedical is positioned in terms of product offerings, innovation, and market share.
- Check if Lifecore Biomedical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Lifecore Biomedical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Lifecore Biomedical stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Lifecore Biomedical is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Above Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Lifecore Biomedical Stock
Researching Lifecore Biomedical's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 74.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.56. Lifecore Biomedical had not issued any dividends in recent years.
To determine if Lifecore Biomedical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lifecore Biomedical's research are outlined below:
| Lifecore Biomedical generated a negative expected return over the last 90 days | |
| Lifecore Biomedical has high historical volatility and very poor performance | |
| Lifecore Biomedical has high likelihood to experience some financial distress in the next 2 years | |
| Lifecore Biomedical generates negative cash flow from operations | |
| Lifecore Biomedical has a poor financial position based on the latest SEC disclosures | |
| About 74.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Greenhaven Road Capitals Updates on Lifecore Biomedical |
Lifecore Biomedical Quarterly Liabilities And Stockholders Equity |
|
Lifecore Biomedical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lifecore Biomedical. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lifecore Biomedical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 6th of June 2024 Next Financial Report | View | |
| 30th of November 2023 Next Fiscal Quarter End | View | |
| 29th of August 2024 Next Fiscal Year End | View | |
| 31st of August 2023 Last Quarter Report | View | |
| 31st of May 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Lifecore Biomedical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Lifecore Biomedical's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-01-06 | 2020-11-30 | 0.01 | 0.02 | 0.01 | 100 | ||
2020-03-31 | 2020-02-29 | 0.03 | 0.04 | 0.01 | 33 | ||
2019-07-30 | 2019-05-31 | -0.02 | -0.01 | 0.01 | 50 | ||
2019-04-03 | 2019-02-28 | 0.03 | 0.04 | 0.01 | 33 | ||
2018-01-03 | 2017-11-30 | 0.01 | 0.02 | 0.01 | 100 | ||
2016-01-05 | 2015-11-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2011-10-04 | 2011-08-31 | 0.06 | 0.07 | 0.01 | 16 | ||
2010-03-30 | 2010-02-28 | 0.08 | 0.07 | -0.01 | 12 |
Know Lifecore Biomedical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lifecore Biomedical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lifecore Biomedical backward and forwards among themselves. Lifecore Biomedical's institutional investor refers to the entity that pools money to purchase Lifecore Biomedical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 375.3 K | Northern Trust Corp | 2024-12-31 | 221.5 K | Tocqueville Asset Management L.p. | 2024-12-31 | 151.7 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 133.2 K | Quinn Opportunity Partners Llc | 2024-12-31 | 127.9 K | Alpha Wave Global Lp | 2024-12-31 | 116.5 K | Ubs Group Ag | 2024-12-31 | 109 K | Boothbay Fund Management, Llc | 2024-12-31 | 87.1 K | Gamco Investors, Inc. Et Al | 2024-12-31 | 86 K | Wynnefield Capital Inc | 2024-12-31 | 4.7 M | Legion Partners Asset Management, Llc | 2024-12-31 | 4.4 M |
Lifecore Biomedical's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 244.37 M.Market Cap |
|
Lifecore Biomedical's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.02) | (0.02) | |
| Return On Capital Employed | 0.02 | 0.01 | |
| Return On Assets | (0.01) | (0.01) | |
| Return On Equity | (0.03) | (0.03) |
Determining Lifecore Biomedical's profitability involves analyzing its financial statements and using various financial metrics to determine if Lifecore Biomedical is a good buy. For example, gross profit margin measures Lifecore Biomedical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lifecore Biomedical's profitability and make more informed investment decisions.
Lifecore Biomedical's Earnings Breakdown by Geography
Evaluate Lifecore Biomedical's management efficiency
Lifecore Biomedical has return on total asset (ROA) of (0.0247) % which means that it has lost $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2958) %, meaning that it created substantial loss on money invested by shareholders. Lifecore Biomedical's management efficiency ratios could be used to measure how well Lifecore Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/24/2025, Return On Tangible Assets is likely to drop to -0.02. In addition to that, Return On Capital Employed is likely to drop to 0.01. At this time, Lifecore Biomedical's Non Currrent Assets Other are relatively stable compared to the past year. As of 03/24/2025, Other Assets is likely to grow to about 25.1 M, while Total Assets are likely to drop slightly above 248.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.17 | 3.96 | |
| Tangible Book Value Per Share | 1.10 | 2.18 | |
| Enterprise Value Over EBITDA | 10.29 | 9.18 | |
| Price Book Value Ratio | 0.70 | 0.74 | |
| Enterprise Value Multiple | 10.29 | 9.18 | |
| Price Fair Value | 0.70 | 0.74 | |
| Enterprise Value | 39 M | 37.1 M |
Lifecore Biomedical showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 0.968 |
Basic technical analysis of Lifecore Stock
As of the 24th of March, Lifecore Biomedical secures the Mean Deviation of 2.8, risk adjusted performance of (0.03), and Standard Deviation of 4.11. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lifecore Biomedical, as well as the relationship between them. Please verify Lifecore Biomedical coefficient of variation and maximum drawdown to decide if Lifecore Biomedical is priced some-what accurately, providing market reflects its recent price of 6.6 per share. Given that Lifecore Biomedical has information ratio of (0.03), we recommend you to check Lifecore Biomedical's last-minute market performance to make sure the company can sustain itself at a future point.Lifecore Biomedical's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lifecore Biomedical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lifecore Biomedical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lifecore Biomedical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Lifecore Biomedical's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Lifecore Biomedical's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 2.8 | |||
| Coefficient Of Variation | (2,556) | |||
| Standard Deviation | 4.11 | |||
| Variance | 16.9 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 28.39 | |||
| Value At Risk | (7.10) | |||
| Potential Upside | 3.85 | |||
| Skewness | (0.16) | |||
| Kurtosis | 3.79 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.31) | |||
| Mean Deviation | 2.8 | |||
| Coefficient Of Variation | (2,556) | |||
| Standard Deviation | 4.11 | |||
| Variance | 16.9 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0) | |||
| Treynor Ratio | (0.32) | |||
| Maximum Drawdown | 28.39 | |||
| Value At Risk | (7.10) | |||
| Potential Upside | 3.85 | |||
| Skewness | (0.16) | |||
| Kurtosis | 3.79 |
Consider Lifecore Biomedical's intraday indicators
Lifecore Biomedical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lifecore Biomedical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 3042.59 | |||
| Daily Balance Of Power | 0.2778 | |||
| Rate Of Daily Change | 1.01 | |||
| Day Median Price | 6.58 | |||
| Day Typical Price | 6.59 | |||
| Price Action Indicator | 0.045 | |||
| Period Momentum Indicator | 0.05 |
Lifecore Biomedical Corporate Filings
| 27th of February 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify | |
| 21st of January 2025 Other Reports | ViewVerify | |
8K | 17th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Lifecore Stock media impact
Far too much social signal, news, headlines, and media speculation about Lifecore Biomedical that are available to investors today. That information is available publicly through Lifecore media outlets and privately through word of mouth or via Lifecore internal channels. However, regardless of the origin, that massive amount of Lifecore data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lifecore Biomedical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lifecore Biomedical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lifecore Biomedical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lifecore Biomedical alpha.
Lifecore Biomedical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Lifecore Biomedical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lifecore Biomedical Corporate Management
| Darren Hieber | Senior Partnerships | Profile | |
| Matt Augustson | Senior Technology | Profile | |
| Aaron Perlitsh | Director Officer | Profile | |
| Thomas Guldager | Senior Operations | Profile | |
| Kara Morley | Senior Resources | Profile |
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.